Press Releases

Date Title and Summary Additional Formats
Toggle Summary GSK Submits EU Filing for Extended Use of Relvar Ellipta in Patients with Controlled Asthma on an ICS/LABA Combination
LONDON --(BUSINESS WIRE)-- GlaxoSmithKline plc (LSE/ NYSE : GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced a submission to the European Medicines Agency (EMA) for the extended use of once-daily Relvar Ellipta (fluticasone furoate/vilanterol, FF/VI), an inhaled corticosteroid (ICS) /
View HTML
Toggle Summary Innoviva to Report Second Quarter Financial Results on July 26 at 5:00 p.m. EDT
BRISBANE, Calif. --(BUSINESS WIRE)-- Innoviva, Inc. (NASDAQ: INVA) announced today that it will report financial results for the second quarter ended June 30, 2017 after market close on Wednesday, July 26, 2017 . Following the earnings release, Innoviva management will host a webcast and conference
View HTML
Toggle Summary Innoviva to Participate in Bank of America Merrill Lynch Healthcare Conference on May 17
BRISBANE, Calif. --(BUSINESS WIRE)-- Innoviva, Inc. (NASDAQ: INVA) today announced that Michael W. Aguiar, Innoviva's President and Chief Executive Officer, and Eric d'Esparbes, the Company's Senior Vice President and Chief Financial Officer, will participate in a fireside chat at the Bank of
View HTML
Toggle Summary Relvar Ellipta Significantly Improved Asthma Control in Salford Lung Study Patients Compared with Their Usual Care
Primary endpoint showed patients initiated with Relvar Ellipta had twice the odds of achieving an improvement in asthma control compared with patients continuing usual care. LONDON --(BUSINESS WIRE)-- GlaxoSmithKline plc (LSE/ NYSE : GSK) and Innoviva Inc (NASDAQ: INVA) today announced positive
View HTML
Toggle Summary Innoviva Reports First Quarter 2017 Financial Results
Royalties earned in Q1 2017 of $43.7 million , up 60% from Q1 2016 Net income for Q1 2017 of $16.8 million (up 280% from Q1 2016), or $0.16 basic earnings per share, and adjusted earnings per share of $0.19 per share Management will host a conference call and webcast today at 5:00 p.m.
View HTML
Toggle Summary Innoviva to Report First Quarter Financial Results on April 27 at 5:00 p.m. EDT
BRISBANE, Calif. --(BUSINESS WIRE)-- Innoviva, Inc. (NASDAQ: INVA) announced today that it will report financial results for the first quarter ended March 31, 2017 after market close on Thursday, April 27, 2017 . Following the earnings release, Innoviva management will host a webcast and conference
View HTML
Toggle Summary Innoviva Announces Preliminary Results of Annual Meeting
Innoviva Shareholders Support All Seven Innoviva Board Members and Management at Annual Meeting BRISBANE, Calif. --(BUSINESS WIRE)-- Innoviva, Inc. (the "Company" or " Innoviva") (NASDAQ: INVA) is pleased to announce that, based on the advice of its proxy solicitor, the Company believes
View HTML
Toggle Summary Innoviva Urges Shareholders to Vote "FOR" All of Innoviva's Value-Creating Directors On the WHITE Proxy Card TODAY
BRISBANE, Calif. --(BUSINESS WIRE)-- Innoviva, Inc. (the "Company" or " Innoviva") (NASDAQ: INVA) today called upon shareholders to make the clear choice to vote FOR the Company's Board of Directors (the "Board"). The Annual Meeting of Stockholders is scheduled to be held tomorrow, April 20, 2017 ,
View HTML
Toggle Summary Innoviva Issues Statement on Upcoming Annual Meeting of Stockholders
Innoviva Board Recommends Shareholders Vote "FOR" All of Innoviva's Qualified Directors on the WHITE Proxy Card Value Creating Strategy Supported by Innoviva's Most Important Partner, GlaxoSmithKline BRISBANE, Calif. --(BUSINESS WIRE)-- Innoviva, Inc.
View HTML
Toggle Summary Innoviva Board Recommends Shareholders Vote "FOR" All of Innoviva's Qualified Directors on the WHITE Proxy Card
BRISBANE, Calif. --(BUSINESS WIRE)-- Innoviva, Inc. (the "Company" or " Innoviva") (NASDAQ: INVA) today announced its Board of Directors has issued the following letter to shareholders in connection with the upcoming Annual Meeting of Stockholders to be held on April 20, 2017 .
View HTML

Copyright Nasdaq. Minimum 15 minutes delayed.

Contact

Innoviva Investor Relations & Media
650.238.9640

For business development inquiries,
please contact bd@inva.com.